loading
Schlusskurs vom Vortag:
$2.31
Offen:
$2.34
24-Stunden-Volumen:
36,679
Relative Volume:
0.22
Marktkapitalisierung:
$47.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-42.05M
KGV:
-0.4007
EPS:
-5.94
Netto-Cashflow:
$-35.26M
1W Leistung:
-7.75%
1M Leistung:
+18.41%
6M Leistung:
-18.77%
1J Leistung:
+108.77%
1-Tages-Spanne:
Value
$2.28
$2.40
1-Wochen-Bereich:
Value
$2.21
$2.60
52-Wochen-Spanne:
Value
$1.04
$5.24

Protara Therapeutics Inc Stock (TARA) Company Profile

Name
Firmenname
Protara Therapeutics Inc
Name
Telefon
646-844-0337
Name
Adresse
345 PARK AVENUE SOUTH, NEW YORK, NY
Name
Mitarbeiter
27
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
TARA's Discussions on Twitter

Vergleichen Sie TARA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
TARA 2.38 47.76M 0 -42.05M -35.26M -5.94
VRTX 449.84 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.06 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.18 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.30 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.17 24.89B 3.30B -501.07M 1.03B 11.54

Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-06-04 Eingeleitet H.C. Wainwright Buy
2021-02-17 Eingeleitet Oppenheimer Outperform
2020-10-19 Eingeleitet Cowen Outperform
2020-07-29 Eingeleitet Guggenheim Buy

Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten

pulisher
Nov 19, 2024

Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com

Nov 19, 2024
pulisher
Nov 18, 2024

HC Wainwright Analysts Decrease Earnings Estimates for TARA - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 18.1% in October - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Protara Therapeutics to Present New Interim Data from Phase - GlobeNewswire

Nov 15, 2024
pulisher
Nov 15, 2024

Protara to Present Key TARA-002 Phase 2 Trial Data for Bladder Cancer Treatment | TARA Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 14, 2024

Woodline Partners LP Acquires Shares in Protara Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Reiterates "Buy" Rating for Protara Therapeutics (NASDAQ:TARA) - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Protara Therapeutics Reports Increased R&D Expenses - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Protara Therapeutics: Q3 Earnings Snapshot - CT Insider

Nov 13, 2024
pulisher
Nov 12, 2024

Protara Therapeutics reports Q3 EPS (50c), consensus (52c) - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Protara Therapeutics: FDA Fast Track Win, Strong Trial Progress Despite Wider Q3 Loss | TARA Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Protara Therapeutics Inc (TARA) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 06, 2024

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - GlobeNewswire

Nov 06, 2024
pulisher
Oct 22, 2024

FDA fast tracks Protara's choline chloride therapy By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 21, 2024

FDA fast tracks Protara's choline chloride therapy - Investing.com

Oct 21, 2024
pulisher
Oct 21, 2024

Protara Therapeutics Granted FDA Fast Track Designation for - GlobeNewswire

Oct 21, 2024
pulisher
Oct 21, 2024

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support - Yahoo Finance

Oct 21, 2024
pulisher
Oct 19, 2024

Protara Therapeutics (FRA:1KPA) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com

Oct 19, 2024
pulisher
Sep 11, 2024

Investing in Protara Therapeutics Inc (TARA) Is Getting More Attractive - Knox Daily

Sep 11, 2024
pulisher
Sep 10, 2024

Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com India

Sep 10, 2024
pulisher
Sep 10, 2024

Opaleye Management Inc. sells shares in Protara Therapeutics By Investing.com - Investing.com Canada

Sep 10, 2024
pulisher
Sep 09, 2024

Protara reveals high choline deficiency in PS patients - Investing.com India

Sep 09, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Results from THRIVE-1, a - GlobeNewswire

Sep 09, 2024
pulisher
Sep 09, 2024

Protara reveals high choline deficiency in PS patients By Investing.com - Investing.com Canada

Sep 09, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire

Sep 09, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - StockTitan

Sep 09, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - StockTitan

Sep 09, 2024
pulisher
Sep 03, 2024

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Sep 03, 2024
pulisher
Sep 02, 2024

Analyzing Genasys Inc (GNSS) After Recent Trading Activity - Knox Daily

Sep 02, 2024
pulisher
Sep 02, 2024

Check Out Protara Therapeutics Inc (TARA)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Investor’s Delight: Protara Therapeutics Inc (TARA) Closes Weak at 2.00, Down -0.99 - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

A year in review: Protara Therapeutics Inc (TARA)’s performance in the last year - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Bowhead Specialty Holdings Inc. (BOW) receives an Outperform rating from RBC Capital Mkts - Knox Daily

Sep 02, 2024
pulisher
Aug 21, 2024

Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period | Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba - Barchart

Aug 21, 2024
pulisher
Aug 21, 2024

Monitoring Protara Therapeutics Inc (TARA) after recent insider movements - Knox Daily

Aug 21, 2024
pulisher
Aug 20, 2024

Protara Therapeutics (NASDAQ:TARA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga

Aug 20, 2024
pulisher
Aug 20, 2024

TARA (Protara Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Aug. 20, 2024) - GuruFocus.com

Aug 20, 2024
pulisher
Aug 19, 2024

Protara Therapeutics (FRA:1KPA) 5-Day RSI : 59.63 (As of Aug. 19, 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

TARA (Protara Therapeutics) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

TARA (Protara Therapeutics) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 18, 2024

TARA (Protara Therapeutics) Peter Lynch Fair Value : N/A (As of Aug. 18, 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 17, 2024

Protara Therapeutics (FRA:1KPA) GF Value Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

Protara Therapeutics (FRA:1KPA) Price-to-Operating-Cash-Flo - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

Protara Therapeutics (FRA:1KPA) Volatility : 109.18% (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

Protara Therapeutics (STU:1KPA) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 16, 2024

Protara Therapeutics (STU:1KPA) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 16, 2024

Protara Therapeutics (STU:1KPA) 3-Year EBITDA Growth Rate : 6.50% (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 13, 2024

Protara Therapeutics (NASDAQ:TARA) Given New $25.00 Price Target at Oppenheimer - Defense World

Aug 13, 2024
pulisher
Aug 09, 2024

Q3 2024 EPS Estimates for Protara Therapeutics, Inc. Increased by Analyst (NASDAQ:TARA) - Defense World

Aug 09, 2024
pulisher
Aug 09, 2024

Protara Therapeutics (NASDAQ:TARA) & Elevation Oncology (NASDAQ:ELEV) Head to Head Review - Defense World

Aug 09, 2024

Finanzdaten der Protara Therapeutics Inc-Aktie (TARA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):